PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 927-932

  Dawson, Rodney ^a   Diacon, Andreas ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Bactericidal activity; Drug resistance; PA 824; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MOLECULAR STRUCTURE; NITROIMIDAZOLES; PYRAZINAMIDE; QUINOLINES; TUBERCULOSIS, PULMONARY;

EID: 84879098265     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.801958     Document Type: Article

References (22)

1. Schroeder EK, de Souza N, Santos DS, et al. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotechnol 2002;3:197-225
2. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010;18:237
3. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature 2011;469:483-90
4. Conde MB, Lapa ESJR. New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis. Drug Dev Res 2011;72:501-8
5. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986-93
6. Iona E, Giannoni F, Pardini M, et al. Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:1537-40
7. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011;15:949-54
8. Li X, Manjunatha UH, Goodwin MB, et al. Synthesis and antitubercular activity of 7-(R)-and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy) -6,7-dihydro-5H-imidazo [2,1-b] [1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett 2008;18:2256-62
9. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-301
10. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009;53:3726-33
11. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010;54:3402-7
12. Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:239-45
13. Diacon AH, Dawson R, du Bois J, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012;56:3027-31
14. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50:2621-5
15. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005;49:2289-93
16. Singh KP, Brown M, Murphy ME, Gillespie SH. Moxifloxacin for tuberculosis. Lancet Infect Dis 2012;12:176; author reply 177-178
17. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-4
18. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:5485-92
19. Diacon AH, Maritz JS, Venter A, et al. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect 2012;18:711-17
20. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010;375:1920-37
21. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405
22. Hewlett D Jr, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995;273:916-17